Company profile
OGT - Pioneers in hybridisation technology
A leading provider of clinical research and diagnostic solutions. We work in partnership with customers to progress the future of genetic-based medicine.
Updated 06 Jun 2026 16:52
Financial period: 1 Apr 2024 to 31 Mar 2025
Reference milestones and recent Companies House filing stream events.
Next confirmation statement due date
Next accounts due date
Last confirmation statement made up date
Last accounts made up date
Company registered at Companies House
1 Oct 2013 to 31 May 2015
Oxford Gene Technology, in collaboration with Professor Mike Griffiths at the University of Birmingham, will develop novel strategies to help implement next generation sequencing (NGS) into routine clinical practice. NGS offers significant benefits in delivery of improved and earlier diagnosis, informed therapeutic selection, and monitoring of disease pro...
1 Dec 2011 to 31 Dec 2014
The aim of this project is to develop a tumour profiling assay based on targeted multiplexed enrichment and next generation sequencing (NGS) of clinically informative genes and variants. Oxford Gene Technology (OGT) will work closely with its partners in Birmingham and Southampton, and the CR-UK Technology hubs to build the assay into an innovative, integ...
1 Oct 2011 to 30 Sep 2013
This project will develop a collaborative business model for the evaluation, and application of molecular biomarkers as companion diagnostics (CDx) in support of drug development projects. The business model will align commercial and clinical objectives of the pharmaceutical and diagnostic partners as well as set in place a mutually beneficial value shari...
